Following nearly two years of negative reports and speculation regarding the safety of drug-eluting stents, manufacturers of the devices had to be pleased with the almost universally positive clinical ...

Following a decision to extend imposed price controls on coronary stents through 2019, India’s National Pharmaceutical Pricing Authority (NPPA) has revised its policies to allow manufacturers to ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/52041d/the_top_60_manufac) has announced the addition of the "The Top 60 ...

New York, NY - In one side's telling, the rivalry pitting Boston Scientific's Taxus TM drug-eluting stent against Johnson & Johnson's Cypher TM can be traced back to a dinner date in 1995, when J&J ...

Johnson & Johnson announced on Wednesday that it would stop manufacturing drug-coated heart stents by the end of the year, abandoning an intensely competitive $4 billion market after a series of ...

The govt added coronary stents to the national list of essential medicines 2015, bringing them under price control, a move opposed by stent manufacturers Exciting, sharp and clear analysis of the ...

Industry sources suggest the pricing change was prompted by the recent Khyati hospital controversy. Prior to this change, all stents were reimbursed at approximately Rs 34,000 regardless of approval ...

Hyderabad (Telangana) [India], April 15 (ANI): Minister for Industries and Commerce, KT Rama Rao on Friday inaugurated the first phase of the stent manufacturing unit of Sahajanand Medical ...

In a major boost for the medical devices manufacturing ecosystem in the state, the country’s largest cardiac stent manufacturer, Sahajanand Medical Technologies (SMT), on Friday inaugurated the first ...